Clinical Trial Detail

NCT ID NCT02900716
Title Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Zhejiang DTRM Biopharma
Indications

CLL/SLL

chronic lymphocytic leukemia

marginal zone B-cell lymphoma

mantle cell lymphoma

follicular lymphoma

Therapies

DTRMWXHS-12 + Everolimus + Pomalidomide

DTRMWXHS-12

DTRMWXHS-12 + Everolimus

Age Groups: adult senior

No variant requirements are available.